**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1(Currently amended). A method for preventing or treating a T cell mediated inflammatory ~~or~~ autoimmune disease, comprising administering to an individual in need thereof a therapeutically effective amount of at least one FGFR 3 inhibitor and a pharmaceutically acceptable carrier, wherein the at least one FGFR 3 inhibitor comprises the antigen-binding portion of an antibody which has a specific affinity for FGFR3 and with the proviso that the T cell mediated inflammatory autoimmune disease is not psoriasis.

Claim 2 (Cancelled).

3(Currently amended). The method according to claim ~~2~~ 1, wherein said at least one FGFR3 inhibitor is a molecule comprising the antigen binding portion of an antibody which has a specific affinity for the extracellular domain of FGFR3.

4(Currently amended). The method according to claim 3, wherein said molecule comprising the antigen-binding portion of an antibody which has a specific affinity for FGFR3 is a monoclonal antibody or a proteolytic fragment thereof.

5(Original).   The method according to claim 4 wherein said monoclonal antibody or proteolytic fragment thereof is an anti-FGFR3 Fab.

6(Currently amended).   The method according to claim ~~34~~ 3, wherein said molecule comprising the antigen-binding portion of an antibody which has a specific affinity for FGFR3 is a single chain Fv set forth in SEQ ID NO:37.

7(Currently amended).   The method according to claim 3, wherein said molecule comprising the antigen-binding portion of an antibody which has a specific affinity for FGFR3 comprising a $V_H$-CDR3 region selected from a group consisting of polypeptides set forth in anyone of SEQ ID NOS:1-9 and a $V_L$-CDR3 region selected from a group consisting of polypeptides set forth in anyone of SEQ ID NOS:10-18.

8(Currently amended).   The method according to claim 7, wherein said molecule comprising the antigen-binding portion of an antibody which has a specific affinity for FGFR3 comprising a $V_H$-CDR3 region set forth in SEQ ID NO:1 and a $V_L$-CDR3 region set forth in SEQ ID NO:10.

9(Currently amended).   The method according to claim 3, wherein said molecule comprising the antigen-binding portion of an antibody which has a specific affinity for FGFR3 comprising a $V_H$ region selected from a group of polypeptides set forth in anyone of SEQ ID NOS:19-27 and a $V_L$ region selected from the group of polypeptides set forth in anyone of SEQ ID NOS:28-36.

10(Currently amended). The method according to claim 9, wherein said molecule comprising the antigen-binding portion of an antibody which has a specific affinity for FGFR3 comprising a $V_H$ region set forth in SEQ ID NO:19 and a $V_L$ region set forth in SEQ ID NO:28.

Claim 11 (Cancelled).

12(Currently amended). The method according to claim 1, wherein the T cell mediated inflammatory autoimmune disease is selected from rheumatoid arthritis, collagen II arthritis, multiple sclerosis, systemic lupus erythematosus, psoriasis, juvenile onset diabetes, Sjogren's disease, thyroid disease, sarcoidosis, autoimmune uveitis, inflammatory bowel disease (Crohn's and ulcerative colitis), celiac disease and myasthenia gravis.

13(Currently amended). The method according to claim 12, wherein the T cell mediated inflammatory autoimmune disease is rheumatoid arthritis.

Claims 14-26 (Cancelled).

27(New). The method according to claim 1, wherein the FGFR3 is encoded by the nucleotide sequence of SEQ ID NO:76.

28(New). The method according to claim 1, wherein the FGFR3 comprises the amino acid sequence of SEQ ID NO:75.